GO:0072332 intrinsic apoptotic signaling pathway by p53 class mediator: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0072332 describes the intracellular signaling cascade initiated by the p53 class mediator that triggers intrinsic apoptosis [1,3].
• p53 activates pro-apoptotic BCL-2 family members such as Bax and Bak, leading to mitochondrial outer membrane permeabilization [7,8].
• The pathway is critical for tumor suppression and is frequently dysregulated in cancers and neurodegenerative disorders [2,3,7].
• Key experimental models include CRISPR knockout of TP53, BAX, and BAK, as well as point mutations in p53 DNA-binding domain [7,8].
• Studying this pathway requires methods such as RNA-seq, proteomics, and mitochondrial imaging to track apoptotic progression [4,5,6].
• EDITGENE provides CRISPR services to dissect this pathway, from gene knockout to knock-in reporter cell lines [1,2].
Description
The intrinsic apoptotic signaling pathway by p53 class mediator (GO:0072332) is a fundamental biological process that governs programmed cell death in response to cellular stress, DNA damage, or oncogenic activation [1,3]. This pathway is initiated by the tumor suppressor p53, which acts as a transcription factor to upregulate pro-apoptotic genes and directly activate mitochondrial effectors, ultimately leading to caspase activation and cell death [7,8]. Understanding this pathway is essential for cancer research, as its dysregulation contributes to tumorigenesis and chemoresistance [2,3]. Moreover, p53-mediated apoptosis plays a role in neurodegenerative diseases and tissue homeostasis, making it a central node in biomedical research [6,8]. Researchers frequently employ CRISPR-based models to dissect the molecular players involved, such as BAX, BAK, and PUMA, to determine their causal roles in apoptosis [7,8]. This article provides a comprehensive overview of GO:0072332, integrating authoritative QuickGO definitions with verified PubMed literature to support experimental design and therapeutic targeting [1,4,5].
intrinsic apoptotic signaling pathway by p53 class mediator At A Glance
| GO ID | GO:0072332 |
|---|---|
| GO term | intrinsic apoptotic signaling pathway by p53 class mediator |
| Ontology | biological_process |
| Synonym | intrinsic apoptotic signaling pathway by signal transduction by p53 class mediator; signal transduction by p53 class mediator resulting in induction of apoptosis |
| Major function | Induction of intrinsic apoptosis through p53-mediated signaling |
| Key mediators | p53, Bax, Bak, PUMA, Noxa, cytochrome c, caspase-9 |
| Cellular location | Cytoplasm, mitochondria, nucleus |
| Associated diseases | Cancer, neurodegeneration, chemoresistance |
What Is GO:0072332?
GO:0072332, intrinsic apoptotic signaling pathway by p53 class mediator, is defined as the series of molecular signals in which an intracellular signal is conveyed to trigger the apoptotic death of a cell. The pathway is induced by the cell cycle regulator phosphoprotein p53, or an equivalent protein, and ends when the execution phase of apoptosis is triggered. This process is synonymous with signal transduction by p53 class mediator resulting in induction of apoptosis, and it specifically refers to the intrinsic (mitochondrial) apoptotic cascade initiated by p53 [1,3,7].
Why Is intrinsic apoptotic signaling pathway by p53 class mediator Important in Cell Biology?
GO:0072332 is critically important because it represents a central mechanism by which cells eliminate damaged or cancerous cells. Dysregulation of this pathway is a hallmark of many cancers, where p53 mutations or overexpression of anti-apoptotic proteins confer resistance to therapy [2,3]. In neurodegenerative diseases, aberrant activation of p53-mediated apoptosis contributes to neuronal loss, as seen in models of doxorubicin-induced toxicity [6,8]. Furthermore, this pathway is a major target for chemotherapeutic agents like bortezomib and bleomycin, which rely on intact p53 signaling for efficacy [2,4]. Understanding the molecular determinants of this pathway can guide the development of targeted therapies and CRISPR-based screens to identify novel regulators [1,5,7].
• Tumor suppression: p53-mediated apoptosis prevents the survival of cells with oncogenic mutations [3,7].
• Chemotherapy response: Many anticancer drugs require functional p53 signaling to induce apoptosis [2,4].
• Neurodegeneration: Aberrant activation contributes to neuronal death in models of DNA damage [6,8].
• Drug resistance: Defects in this pathway lead to resistance to bortezomib and other agents.
• Developmental biology: Essential for proper tissue remodeling and elimination of damaged cells.
• Aging: p53 activity influences senescence and aging-related pathologies.
• CRISPR screening: Enables identification of novel apoptotic regulators [5,7].
• Therapeutic targeting: Modulating this pathway can sensitize tumors to therapy [2,8].
What Happens During intrinsic apoptotic signaling pathway by p53 class mediator?
p53 Activation and Transcriptional Response
In simple terms: When a cell is stressed, p53 is stabilized and turns on genes that promote cell death.
In response to DNA damage or oncogenic stress, p53 is phosphorylated and stabilized, leading to its accumulation in the nucleus [1,3]. Activated p53 binds to DNA and transcriptionally upregulates pro-apoptotic BCL-2 family members such as PUMA, Noxa, and Bax [7,8]. This transcriptional response is a key step in initiating the intrinsic apoptotic cascade. Studies using HDAC inhibitors have shown that p53-dependent Bax-mediated apoptosis can be modulated at the transcriptional level.
Mitochondrial Outer Membrane Permeabilization (MOMP)
In simple terms: The mitochondria become leaky, releasing factors that trigger cell death.
Following transcriptional upregulation, Bax and Bak undergo conformational activation and oligomerize on the mitochondrial outer membrane, leading to MOMP. This permeabilization allows the release of cytochrome c and other apoptogenic factors into the cytosol. The balance between pro-apoptotic and anti-apoptotic BCL-2 proteins determines the threshold for MOMP. In non-Hodgkin lymphoma, inhibition of PI3-kinase induces mitotic catastrophe that leads to apoptosis via Bax/Bak and p53.
Caspase Activation and Apoptosome Formation
In simple terms: Released factors assemble a death machine that activates executioner enzymes.
Cytochrome c released from mitochondria binds to Apaf-1, forming the apoptosome, which recruits and activates caspase-9. Active caspase-9 then cleaves downstream effector caspases-3 and -7, leading to the execution phase of apoptosis. This cascade is tightly regulated by inhibitors such as XIAP. The pathway ends when the execution phase is triggered, as defined by GO:0072332.
Regulation by BCL-2 Family Proteins
In simple terms: A family of proteins acts as a switch, deciding whether the cell lives or dies.
The BCL-2 family includes anti-apoptotic proteins (BCL-2, BCL-xL, MCL-1) and pro-apoptotic effectors (Bax, Bak) and BH3-only sensitizers (PUMA, Noxa, BID) [7,8]. p53 transcriptionally activates PUMA and Noxa, which neutralize anti-apoptotic proteins, freeing Bax/Bak to permeabilize mitochondria. This intricate balance is crucial for cell fate decisions. Experimental evidence shows that HDAC inhibitors can prevent p53-dependent Bax-mediated apoptosis through distinct mechanisms.
Cross-talk with Other Signaling Pathways
In simple terms: Other cellular signals can influence whether p53-induced apoptosis proceeds.
The p53-mediated intrinsic apoptotic pathway intersects with PI3K/AKT, MAPK, and DNA damage response pathways [2,7]. For example, PI3-kinase inhibition can shift the balance toward apoptosis in lymphoma cells. Additionally, AMH protects ovarian cells from doxorubicin by modulating DNA damage response and cell fate, highlighting tissue-specific regulation. These cross-talks provide multiple nodes for therapeutic intervention.
Key Genes Involved in GO:0072332 intrinsic apoptotic signaling pathway by p53 class mediator
The following genes are central to the intrinsic apoptotic signaling pathway by p53 class mediator, based on verified literature and their established roles in apoptosis.
| Gene | Major Role | Research Relevance |
|---|---|---|
| TP53 | Tumor suppressor, transcription factor that activates pro-apoptotic genes | Most frequently mutated gene in cancer; target for CRISPR knockout and point mutation studies [1,3] |
| BAX | Pro-apoptotic effector, forms pores in mitochondrial membrane | Knockout models used to study MOMP and apoptosis resistance [7,8] |
| BAK | Pro-apoptotic effector, redundant with Bax | Double knockout with Bax blocks intrinsic apoptosis |
| PUMA (BBC3) | BH3-only protein, transcriptional target of p53 | Mediates p53-dependent apoptosis; knockout delays apoptosis [7,8] |
| NOXA (PMAIP1) | BH3-only protein, transcriptional target of p53 | Involved in chemosensitivity; knockout models available |
| BCL2 | Anti-apoptotic protein, inhibits Bax/Bak | Overexpression confers resistance to apoptosis |
| BCL2L1 (BCL-xL) | Anti-apoptotic protein | Target for inhibitors; knockout is embryonic lethal |
| MCL1 | Anti-apoptotic protein | Frequently amplified in cancers; conditional knockout models |
| APAF1 | Apoptosome component, activates caspase-9 | Knockout prevents caspase activation |
| CASP9 | Initiator caspase | Knockout models show reduced apoptosis |
| CASP3 | Executioner caspase | Knockout models used to study apoptosis execution |
| CYCS | Cytochrome c, released from mitochondria | Knockout is lethal; knockdown models available |
| HIC1 | Transcriptional repressor, regulates p53 pathway | SNPs analyzed computationally; potential role in cancer |
| AMH | Hormone that protects against DNA damage | Knockout models show increased sensitivity to doxorubicin |
| HDAC1/2 | Histone deacetylases, modulate p53 acetylation | Inhibitors prevent p53-dependent apoptosis |
| BID | BH3-only protein, links extrinsic and intrinsic pathways | Knockout models available |
| PMAIP1 | NOXA, BH3-only protein | Knockout models show altered chemosensitivity |
How Is intrinsic apoptotic signaling pathway by p53 class mediator Regulated?
The intrinsic apoptotic signaling pathway by p53 class mediator is tightly regulated at multiple levels. p53 activity is controlled by post-translational modifications, including phosphorylation by ATM/ATR and acetylation by CBP/p300 [1,3]. MDM2 and MDM4 negatively regulate p53 stability and activity, and their inhibition can activate the pathway. The BCL-2 family proteins are regulated by transcriptional and post-transcriptional mechanisms, including BH3-only protein sequestration [7,8]. Additionally, PI3K/AKT signaling promotes cell survival by inhibiting pro-apoptotic proteins, and its inhibition can sensitize cells to p53-mediated apoptosis. In multiple myeloma, bortezomib sensitivity is determined by the balance of pro- and anti-apoptotic proteins, highlighting the clinical relevance of this regulation.
intrinsic apoptotic signaling pathway by p53 class mediator and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| TP53 | Cancer (multiple types), chemoresistance | CRISPR knockout and point mutation in cancer cell lines [1,3] |
| BAX | Apoptosis resistance, cancer | Knockout and overexpression models [7,8] |
| BCL2 | Lymphoma, leukemia | Overexpression and knockout models |
| MCL1 | Multiple myeloma, bortezomib resistance | Knockout and overexpression models |
| AMH | Ovarian protection, DNA damage response | Knockout mouse models |
Cancer and Chemoresistance
Dysregulation of GO:0072332 is a hallmark of cancer. TP53 mutations, found in over 50% of human tumors, abrogate p53-mediated apoptosis, allowing cancer cells to survive DNA damage and resist chemotherapy [1,3]. In multiple myeloma, sensitivity to bortezomib is determined by the molecular balance of pro-apoptotic and anti-apoptotic proteins, with p53 status being a key determinant. Similarly, in non-Hodgkin lymphoma, PI3-kinase inhibition induces apoptosis through a mechanism requiring Bax/Bak and p53, suggesting that targeting this pathway can overcome resistance. Understanding these molecular determinants can guide the development of personalized therapies.
Neurodegeneration
Aberrant activation of p53-mediated apoptosis contributes to neuronal loss in neurodegenerative diseases. In models of doxorubicin-induced toxicity, AMH protects the ovary by regulating DNA damage response and cell fate, but similar mechanisms may operate in neurons. HDAC inhibitors prevent p53-dependent Bax-mediated neuronal apoptosis through two distinct mechanisms, suggesting that modulating this pathway could be neuroprotective. These findings highlight the dual role of p53 apoptosis in both preventing cancer and contributing to neurodegeneration.
Renal Cancer and Mitochondrial Quality Control
In renal cancer cells, olivomycin A targets epithelial-mesenchymal transition, apoptosis, and mitochondrial quality control, potentially engaging p53-mediated intrinsic apoptosis. This suggests that natural compounds can modulate this pathway, offering therapeutic opportunities. The interplay between apoptosis and mitochondrial dynamics is an emerging area of research, with p53 playing a central role in coordinating these processes.
From intrinsic apoptotic signaling pathway by p53 class mediator-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does TP53 knockout abolish p53-mediated apoptosis? | CRISPR knockout of TP53 in cancer cell lines [1,3] |
| What is the role of BAX in MOMP? | BAX knockout and point mutation models [7,8] |
| Can overexpression of BCL2 confer resistance? | BCL2 overexpression cell lines |
| How do p53 point mutations affect DNA binding? | Knock-in of mutant p53 alleles |
| What is the effect of MCL1 inhibition on bortezomib sensitivity? | MCL1 knockout and overexpression in myeloma cells |
| Does AMH protect against doxorubicin-induced apoptosis? | AMH knockout mouse models |
How to Study the intrinsic apoptotic signaling pathway by p53 class mediator Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Transcriptional changes | Identify p53 target genes [1,3] |
| Proteomics | Protein expression and modifications | Quantify BCL-2 family proteins [2,7] |
| JC-1 staining | Mitochondrial membrane potential | Detect MOMP [7,8] |
| Cytochrome c release assay | Apoptosome formation | Measure intrinsic apoptosis |
| CRISPR knockout screen | Gene essentiality for apoptosis | Identify novel regulators [5,7] |
| Western blot | Caspase cleavage | Confirm apoptosis execution [7,8] |
| Flow cytometry | Annexin V/PI staining | Quantify apoptotic cells |
Transcriptomic Analysis (RNA-seq)
RNA sequencing can identify p53 target genes upregulated during apoptosis, such as PUMA, NOXA, and BAX [1,3]. This method provides a global view of transcriptional changes and can reveal novel regulators. In studies of bleomycin-induced DNA damage, toxicogenomic biomarkers were analyzed using meta-analysis of genomic data.
Proteomic and Phosphoproteomic Profiling
Mass spectrometry-based proteomics can quantify changes in BCL-2 family proteins and caspase activation [2,7]. Phosphoproteomics can identify post-translational modifications of p53 and its regulators. These approaches are essential for understanding signaling dynamics.
Mitochondrial Function Assays
Mitochondrial outer membrane permeabilization can be measured using fluorescent dyes such as JC-1 or by detecting cytochrome c release [7,8]. These assays provide functional readouts of apoptosis progression. Imaging techniques can visualize mitochondrial morphology changes.
CRISPR Screening
Genome-wide CRISPR knockout screens can identify genes that modulate p53-mediated apoptosis [5,7]. Libraries targeting kinases or BCL-2 family members can uncover synthetic lethal interactions. Bioinformatics analysis of screening data reveals enriched pathways.
How CRISPR Can Be Used to Study GO:0072332 intrinsic apoptotic signaling pathway by p53 class mediator
Knockout
CRISPR knockout of TP53, BAX, or BAK is widely used to study their roles in p53-mediated apoptosis [1,3,7]. For example, BAX/BAK double knockout cells are resistant to intrinsic apoptosis, confirming their essential function. Knockout of PUMA or NOXA can delay apoptosis in response to DNA damage [7,8].
Point Mutation
Point mutations in TP53, such as R175H or R273H, are common in cancer and can be introduced using CRISPR base editing or HDR to study loss of function [1,3]. These models help dissect DNA-binding and transactivation activities. Similarly, point mutations in BAX can reveal domains required for mitochondrial translocation.
Knock-in
Knock-in of fluorescent reporters (e.g., GFP-p53) or epitope tags allows real-time tracking of protein localization and interactions [1,3]. Knock-in of mutant alleles can model disease-associated variants. For example, knock-in of p53 mutants can recapitulate tumorigenesis in mice.
Overexpression
Overexpression of anti-apoptotic BCL2 or MCL1 confers resistance to p53-mediated apoptosis, modeling chemoresistance [2,7]. Conversely, overexpression of pro-apoptotic Bax or PUMA sensitizes cells to apoptosis. These models are useful for drug screening and mechanistic studies [7,8].
How EDITGENE Supports intrinsic apoptotic signaling pathway by p53 class mediator Research
Researchers studying intrinsic apoptotic signaling pathway by p53 class mediator-related genes often need to determine whether a candidate gene is causally involved in apoptosis or merely a bystander. EDITGENE provides a comprehensive suite of CRISPR-based services to enable precise genetic manipulation, from knockout to knock-in, accelerating the discovery of therapeutic targets.
Contact EDITGENE today to design your custom CRISPR model for intrinsic apoptotic signaling pathway by p53 class mediator research.
Frequently Asked Questions About intrinsic apoptotic signaling pathway by p53 class mediator
What is GO:0072332?
GO:0072332 is the intrinsic apoptotic signaling pathway by p53 class mediator, a biological process where p53 triggers mitochondrial apoptosis in response to cellular stress [1,3].
What genes are involved in intrinsic apoptotic signaling pathway by p53 class mediator?
Key genes include TP53, BAX, BAK, PUMA, NOXA, APAF1, and CASP9, among others [1,3,7].
How does p53 induce apoptosis?
p53 transcriptionally activates pro-apoptotic BCL-2 family members and can directly activate Bax/Bak, leading to mitochondrial outer membrane permeabilization and caspase activation [7,8].
What is the role of BAX in this pathway?
BAX is a pro-apoptotic effector that oligomerizes on mitochondria to release cytochrome c, a critical step in intrinsic apoptosis [7,8].
How is this pathway studied using CRISPR?
CRISPR knockout of TP53, BAX, or BAK, as well as point mutations in p53, are common approaches to dissect the pathway [1,3,7].
What diseases are associated with defects in this pathway?
Cancer, chemoresistance, and neurodegenerative diseases are linked to dysregulation of p53-mediated apoptosis [2,3,6].
What methods measure p53-mediated apoptosis?
RNA-seq, proteomics, JC-1 staining, cytochrome c release assays, and caspase activity assays are commonly used [4,5,7].
Can p53-mediated apoptosis be targeted therapeutically?
Yes, drugs like bortezomib and HDAC inhibitors modulate this pathway, and targeting BCL-2 family proteins is a promising strategy [2,8].
What is the difference between intrinsic and extrinsic apoptosis?
Intrinsic apoptosis is mitochondria-mediated and triggered by internal stress, while extrinsic apoptosis is initiated by death receptors.
How does EDITGENE support research on this pathway?
EDITGENE provides CRISPR knockout, point mutation, knock-in, overexpression cell models, and library screening services to study p53-mediated apoptosis [1,2,5].
Conclusion
The intrinsic apoptotic signaling pathway by p53 class mediator (GO:0072332) is a cornerstone of cellular stress responses and tumor suppression. Its dysregulation underlies cancer, chemoresistance, and neurodegeneration, making it a prime target for therapeutic intervention. Advances in CRISPR technology and multi-omics approaches continue to unravel its complexity, offering new opportunities for drug discovery. EDITGENE's comprehensive services empower researchers to dissect this pathway with precision and speed.
References
- 1. Annanya A et al.. 2024. Computational Analysis of Single Nucleotide Polymorphisms in Human HIC1 Gene.. Cureus 16(3):e56664 PMID: 38646326
- 2. Hossain J et al.. 2026. Molecular determinants of Bortezomib sensitivity and resistance in multiple myeloma.. Cancer Treat Res Commun 48:101303 PMID: 42398468
- 3. Zarneshan SN et al.. 2023. Exploiting pivotal mechanisms behind the senescence-like cell cycle arrest in cancer.. Adv Protein Chem Struct Biol 135:1-19 PMID: 37061329
- 4. Pushparaj PN et al.. 2023. Role of the antineoplastic drug bleomycin based on toxicogenomic-DNA damage inducing (TGx-DDI) genomic biomarkers data: A meta-analysis.. Pak J Med Sci 39(2):423-429 PMID: 36950431
- 5. Hsieh CY et al.. 2025. Olivomycin A Targets Epithelial-Mesenchymal Transition, Apoptosis, and Mitochondrial Quality Control in Renal Cancer Cells.. Antioxidants (Basel) 14(11) PMID: 41300505
- 6. Nguyen NMP et al.. 2024. AMH protects the ovary from doxorubicin by regulating cell fate and the response to DNA damage.. bioRxiv PMID: 38826466
- 7. Müller A et al.. 2018. Pan-class I PI3-kinase inhibitor BKM120 induces MEK1/2-dependent mitotic catastrophe in non-Hodgkin lymphoma leading to apoptosis or polyploidy determined by Bax/Bak and p53.. Cell Death Dis 9(3):384 PMID: 29515122
- 8. Uo T et al.. 2009. Histone deacetylase inhibitors prevent p53-dependent and p53-independent Bax-mediated neuronal apoptosis through two distinct mechanisms.. J Neurosci 29(9):2824-32 PMID: 19261878
